Missing the mark on prostate-specific antigen screening.

摘要

Current evidence suggests that younger men (ie, <70 years) and those with higher-grade cancers benefit from PSA screening and early intervention. Two screening trials reviewed by the task force demonstrated a small—but significant—survival benefit associated with screening for men younger than age 70 years.4-5 In contrast, the United States Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial showed no mortality benefits from PSA screening.6 However, PSA testing in the study's usual care group was quite high (up to 52%), raising concerns about the study's ability to answer the question of interest.